Why we should not treat patients with stage II colon cancer

Shanmuga P. Subbiah, Jean L Grem

Research output: Contribution to journalArticle

Abstract

Research assessing the worth of adjuvant chemotherapy for stage II colon cancer has been ongoing for several decades. The majority of studies have not demonstrated a significant improvement in survival. Despite this, many patients with stage II disease deemed to be at high-risk for recurrence do receive postoperative chemotherapy. The benefit of adjuvant therapy in such high-risk patients has been suggested by retrospective analyses of phase III trials. Molecular and genetic factors are being investigated to learn if they can predict those who might benefit most from adjuvant therapy. The results of randomized trials and pooled analyses will be reviewed to argue that the majority of stage II colon cancer patients should not receive adjuvant chemotherapy. Prospective studies addressing the benefit of adjuvant chemotherapy in high-risk patients are a high priority.

Original languageEnglish (US)
Pages (from-to)204-209
Number of pages6
JournalCurrent Colorectal Cancer Reports
Volume8
Issue number3
DOIs
StatePublished - Sep 1 2012

Fingerprint

Colonic Neoplasms
Adjuvant Chemotherapy
Molecular Biology
Prospective Studies
Recurrence
Drug Therapy
Survival
Therapeutics
Research

Keywords

  • Adjuvant therapy
  • Chromosome instability
  • Colon cancer
  • Fluorouracil
  • Leucovorin
  • Levamisole
  • Lymph node status
  • Microsatellite instability
  • Oxaliplatin
  • Prognosis
  • SEER

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology

Cite this

Why we should not treat patients with stage II colon cancer. / Subbiah, Shanmuga P.; Grem, Jean L.

In: Current Colorectal Cancer Reports, Vol. 8, No. 3, 01.09.2012, p. 204-209.

Research output: Contribution to journalArticle

@article{5420bff16ee2485c8c396e26e2fa949d,
title = "Why we should not treat patients with stage II colon cancer",
abstract = "Research assessing the worth of adjuvant chemotherapy for stage II colon cancer has been ongoing for several decades. The majority of studies have not demonstrated a significant improvement in survival. Despite this, many patients with stage II disease deemed to be at high-risk for recurrence do receive postoperative chemotherapy. The benefit of adjuvant therapy in such high-risk patients has been suggested by retrospective analyses of phase III trials. Molecular and genetic factors are being investigated to learn if they can predict those who might benefit most from adjuvant therapy. The results of randomized trials and pooled analyses will be reviewed to argue that the majority of stage II colon cancer patients should not receive adjuvant chemotherapy. Prospective studies addressing the benefit of adjuvant chemotherapy in high-risk patients are a high priority.",
keywords = "Adjuvant therapy, Chromosome instability, Colon cancer, Fluorouracil, Leucovorin, Levamisole, Lymph node status, Microsatellite instability, Oxaliplatin, Prognosis, SEER",
author = "Subbiah, {Shanmuga P.} and Grem, {Jean L}",
year = "2012",
month = "9",
day = "1",
doi = "10.1007/s11888-012-0136-3",
language = "English (US)",
volume = "8",
pages = "204--209",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - Why we should not treat patients with stage II colon cancer

AU - Subbiah, Shanmuga P.

AU - Grem, Jean L

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Research assessing the worth of adjuvant chemotherapy for stage II colon cancer has been ongoing for several decades. The majority of studies have not demonstrated a significant improvement in survival. Despite this, many patients with stage II disease deemed to be at high-risk for recurrence do receive postoperative chemotherapy. The benefit of adjuvant therapy in such high-risk patients has been suggested by retrospective analyses of phase III trials. Molecular and genetic factors are being investigated to learn if they can predict those who might benefit most from adjuvant therapy. The results of randomized trials and pooled analyses will be reviewed to argue that the majority of stage II colon cancer patients should not receive adjuvant chemotherapy. Prospective studies addressing the benefit of adjuvant chemotherapy in high-risk patients are a high priority.

AB - Research assessing the worth of adjuvant chemotherapy for stage II colon cancer has been ongoing for several decades. The majority of studies have not demonstrated a significant improvement in survival. Despite this, many patients with stage II disease deemed to be at high-risk for recurrence do receive postoperative chemotherapy. The benefit of adjuvant therapy in such high-risk patients has been suggested by retrospective analyses of phase III trials. Molecular and genetic factors are being investigated to learn if they can predict those who might benefit most from adjuvant therapy. The results of randomized trials and pooled analyses will be reviewed to argue that the majority of stage II colon cancer patients should not receive adjuvant chemotherapy. Prospective studies addressing the benefit of adjuvant chemotherapy in high-risk patients are a high priority.

KW - Adjuvant therapy

KW - Chromosome instability

KW - Colon cancer

KW - Fluorouracil

KW - Leucovorin

KW - Levamisole

KW - Lymph node status

KW - Microsatellite instability

KW - Oxaliplatin

KW - Prognosis

KW - SEER

UR - http://www.scopus.com/inward/record.url?scp=84869135179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869135179&partnerID=8YFLogxK

U2 - 10.1007/s11888-012-0136-3

DO - 10.1007/s11888-012-0136-3

M3 - Article

AN - SCOPUS:84869135179

VL - 8

SP - 204

EP - 209

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 3

ER -